<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00271401</url>
  </required_header>
  <id_info>
    <org_study_id>CR006265</org_study_id>
    <nct_id>NCT00271401</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab</brief_title>
  <official_title>A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centocor, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness and safety of intracoronary
      stenting with or without abciximab, an anti-platelet therapy, and conventional coronary
      angioplasty with abciximab in patients undergoing percutaneous coronary intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the
      safety and effectiveness of intracoronary stenting with or without abciximab, an
      anti-platelet therapy, and conventional coronary angioplasty with abciximab in patients
      undergoing percutaneous coronary intervention. Patients will be randomly assigned to one of
      three treatment groups: coronary angioplasty plus abciximab, intracoronary stent plus
      abciximab, or intracoronary stent plus placebo. The primary measures of effectiveness will be
      a 30-day composite, clinical outcome as determined by the number of deaths, myocardial
      infarctions, or urgent repeat revascularizations. Please see attached results.

      Patients will receive one of three different treatments: Coronary angioplasty plus abciximab;
      Intracoronary stent plus abciximab; or Intracoronary stent plus placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1996</start_date>
  <completion_date type="Actual">September 1997</completion_date>
  <primary_completion_date type="Actual">September 1997</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With any one of these: Deaths, Myocardial Infarctions, or Urgent Repeat Revascularizations</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Particpants with Angiographic Outcome, Death or Myocardial Infraction and Cardiovascular Functional Status</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2399</enrollment>
  <condition>Angioplasty, Transluminal, Percutaneous Coronary</condition>
  <arm_group>
    <arm_group_label>Angioplasty With Abciximab Plus Low-Dose Heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive conventional angioplasty/atherectomy along with bolus abciximab 0.25 milligram per kilogram (mg/kg) of body weight followed by a 0.125 microgram per kilogram per minute (mcg/kg/minute) infusion for 12 hours plus 7 unit per kilogram per hour (U/kg/hr) continuous infusion of heparin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intracoronary Stent With Reo Pro Plus Low Dose Heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intracoronary stent along with receive bolus abciximab 0.25 mg/kg of body weight followed by a 0.125 mcg/kg/minute infusion for 12 hours plus 7 U/kg/hr continuous infusion of heparin (low dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intracoronary Stent With Placebo Plus Standard Dose Heparin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive intracoronary stent along with bolus placebo followed by placebo infusion for 12 hours plus 10 U/kg/hr continuous infusion of heparin (standard dose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Angioplasty</intervention_name>
    <arm_group_label>Angioplasty With Abciximab Plus Low-Dose Heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intracoronary Stent</intervention_name>
    <arm_group_label>Intracoronary Stent With Reo Pro Plus Low Dose Heparin</arm_group_label>
    <arm_group_label>Intracoronary Stent With Placebo Plus Standard Dose Heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abxicimab</intervention_name>
    <arm_group_label>Angioplasty With Abciximab Plus Low-Dose Heparin</arm_group_label>
    <arm_group_label>Intracoronary Stent With Reo Pro Plus Low Dose Heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <arm_group_label>Angioplasty With Abciximab Plus Low-Dose Heparin</arm_group_label>
    <arm_group_label>Intracoronary Stent With Reo Pro Plus Low Dose Heparin</arm_group_label>
    <arm_group_label>Intracoronary Stent With Placebo Plus Standard Dose Heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Intracoronary Stent With Placebo Plus Standard Dose Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients referred for elective or urgent percutaneous coronary intervention

          -  Who are suitable candidates for either conventional angioplasty or primary
             intracoronary stent implantation

          -  Having a target artery (native or graft) stenosis of &gt;= 60% (visual estimation)

        Exclusion Criteria:

          -  Patients with acute ST-segment elevation myocardial infarction within the previous 12
             hours

          -  With a planned staged procedure or having an unprotected left main coronary artery
             stenosis &gt; 50%

          -  With active internal bleeding, having a condition that may increase the risk of
             bleeding, or receiving ongoing treatment with an oral anticoagulant at the time of
             study entry

          -  Having had a percutaneous coronary intervention within the previous 3 months or prior
             intracoronary stent placement in a target vessel

          -  Having hypertension with systolic blood pressure &gt; 180 mm Hg or diastolic blood
             pressure &gt; 100 mm Hg at the time of study entry, or a platelet count &lt; 100,000/Î¼L at
             baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor, Inc.</affiliation>
  </overall_official>
  <results_reference>
    <citation>Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF, Anderson KM, Califf RM. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 1999 Dec 11;354(9195):2019-24. Erratum in: Lancet 2000 Mar 25;355(9209):1104.</citation>
    <PMID>10636365</PMID>
  </results_reference>
  <results_reference>
    <citation>EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998 Jul 11;352(9122):87-92.</citation>
    <PMID>9672272</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2005</study_first_submitted>
  <study_first_submitted_qc>December 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2006</study_first_posted>
  <last_update_submitted>May 22, 2015</last_update_submitted>
  <last_update_submitted_qc>May 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stents</keyword>
  <keyword>Angioplasty, Transluminal, Percutaneous Coronary</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

